RxDoctor Payments Data

Damon Dyche, MD

Urology · Ames, IANPI 1194930081

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,013 of the $4,160 with a category attached, or 72.4%. 9 manufacturers reported payments, led by Axonics, Inc. at 32.6% of the total. Reporting peaked in 2019 at $1,300 and has fallen 97.8% since, to $29 in 2025.

$4,160in general payments, 2019–2025

Across 41 payments — averaging $101.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Valencia Technologies Corporation$1K
  • Neotract Inc.$984
  • Intuitive Surgical$360
  • Astellas Pharma US Inc$165
  • AbbVie$51
  • plus $68 from 3 others

What the payments were for

  • Travel & lodging$3,01372%
  • Food & beverage$98024%
  • Education$1674%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,160 in reported general payments places this provider in the 70th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$436,391
Medicare patients
1,065
Services billed
11,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide36$505,991
MyrbetriqMirabegron114$55,819
Trospium Chloride286$13,315
Tamsulosin Hcl979$8,711
Oxybutynin Chloride ErOxybutynin Chloride478$8,144
Methenamine Hippurate96$5,261
Testosterone11$4,234
Potassium Citrate ErPotassium Citrate66$3,888
Solifenacin Succinate56$3,318
Finasteride261$2,869
Estradiol34$2,721
Testosterone Cypionate49$2,660
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$1,286
Silodosin27$1,167
Gentamicin Sulfate41$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$165$561,810150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 114 urology providers in Iowa.

Other urology in Ames

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →